HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Judge Knocks Down FTC Substantiation Bar In POM Wonderful Case

This article was originally published in The Tan Sheet

Executive Summary

An FTC administrative law judge says the agency cannot require randomized controlled trials to substantiate nutrient claims. POM Wonderful calls the decision “a huge win,” but the firm still received a cease-and-desist order for its pomegranate juice and supplement claims.

You may also be interested in...



Nutrition Scientists Float “Least-Harm Strategy” To Allow Health Claims

Presenters at the IFT Wellness conference recommend that nutrition science move beyond randomized controlled trials – which typically are ill-suited to assess nutrient benefits – so development of new food and supplement products is not impeded.

Supplement Claim Ruling Rejects FTC View Of “Competent And Reliable” Evidence

In a decision that suggests FTC may have to broaden what it considers competent and reliable evidence, a federal court in Florida rules supplement firm Garden of Life performed adequate due diligence in making claims and was not in contempt of an order for permanent injunction.

Fair Standard Remains For Supplement, Drug Claim Substantiation – FTC

The Federal Trade Commission says consent orders that require more clinical tests to substantiate health claims than are required for other product categories are fair because they are based on the nature of the claims, agency officials say.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel